FY2026 EPS Estimates for Veracyte Raised by Leerink Partnrs

Veracyte, Inc. (NASDAQ:VCYT) – Analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of Veracyte in a research report issued to clients and investors on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will earn $0.80 per share for the year, up from their prior forecast of $0.79. The consensus estimate for Veracyte’s current full-year earnings is $0.68 per share.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The firm had revenue of $118.63 million for the quarter, compared to analyst estimates of $110.73 million. During the same period in the prior year, the firm posted ($0.39) earnings per share.

Other research analysts have also issued reports about the company. Needham & Company LLC reissued a “buy” rating and set a $51.00 target price on shares of Veracyte in a report on Tuesday, February 25th. Craig Hallum assumed coverage on shares of Veracyte in a report on Thursday, March 20th. They issued a “buy” rating and a $45.00 price objective on the stock. UBS Group raised their target price on shares of Veracyte from $46.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Stephens reiterated an “overweight” rating and issued a $45.00 price target on shares of Veracyte in a research note on Wednesday, March 26th. Finally, Guggenheim cut their price objective on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Veracyte Stock Up 1.7 %

Shares of NASDAQ VCYT opened at $31.13 on Tuesday. The business’s 50 day moving average price is $32.79 and its two-hundred day moving average price is $37.35. The company has a market cap of $2.43 billion, a PE ratio of -207.53 and a beta of 2.03. Veracyte has a twelve month low of $19.09 and a twelve month high of $47.32.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp raised its position in shares of Veracyte by 49.7% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 237 shares in the last quarter. Versant Capital Management Inc increased its stake in Veracyte by 1,267.6% in the first quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 862 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Veracyte during the fourth quarter valued at approximately $64,000. US Bancorp DE lifted its stake in Veracyte by 57.4% during the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 647 shares during the last quarter. Finally, Principal Securities Inc. boosted its holdings in shares of Veracyte by 34.1% in the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 485 shares in the last quarter.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.